Cargando…

FGFR3-TACC3 fusion in solid tumors: mini review

Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Ricardo, Carneiro, Benedito A., Taxter, Timothy, Tavora, Fabio A., Kalyan, Aparna, Pai, Sachin A., Chae, Young Kwang, Giles, Francis J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342462/ https://www.ncbi.nlm.nih.gov/pubmed/27409839 http://dx.doi.org/10.18632/oncotarget.10482

Ejemplares similares

FGFR3–TACC3: A novel gene fusion in cervical cancer
por: Carneiro, Benedito A., et al.
Publicado: (2015)

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
por: Best, Sarah A., et al.
Publicado: (2018)

FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma
por: Gött, Hanna, et al.
Publicado: (2022)

A metabolic function of FGFR3-TACC3 gene fusions in cancer
por: Frattini, Véronique, et al.
Publicado: (2018)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

FGFR3–TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle
por: Sarkar, Sourav, et al.
Publicado: (2017)

Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions
por: Tamura, Ryo, et al.
Publicado: (2018)

Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
por: Métais, Alice, et al.
Publicado: (2023)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019)

RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine
por: Parker Kerrigan, Brittany C, et al.
Publicado: (2020)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples
por: Kurobe, Masahiro, et al.
Publicado: (2016)

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
por: Chae, Young Kwang, et al.
Publicado: (2016)

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling
por: Nelson, Katelyn N., et al.
Publicado: (2018)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling
por: Daly, C, et al.
Publicado: (2017)

Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis
por: Lombardi, Benedetta, et al.
Publicado: (2017)

Aberrations of TACC1 and TACC3 are associated with ovarian cancer
por: Lauffart, Brenda, et al.
Publicado: (2005)

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2017)

The challenge of developmental therapeutics for adrenocortical carcinoma
por: Costa, Ricardo, et al.
Publicado: (2016)

Histology-specific FGFR2 alterations and FGFR2-TACC2 fusion in mixed adenoid cystic and neuroendocrine small cell carcinoma of the uterine cervix
por: Gill, Corey M., et al.
Publicado: (2020)

TACC3 in personalized medicine
por: Murata, Stephen, et al.
Publicado: (2015)

Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability
por: Wang, Clark G., et al.
Publicado: (2023)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017)

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling
por: Chae, Young Kwang, et al.
Publicado: (2015)

Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review
por: Broggi, Giuseppe, et al.
Publicado: (2022)

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
por: Chae, Young Kwang, et al.
Publicado: (2016)

TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis
por: Wang, June, et al.
Publicado: (2017)

TACC3 Is Important for Correct Progression of Meiosis in Bovine Oocytes
por: Mahdipour, Mahdi, et al.
Publicado: (2015)

Genomic landscape of DNA repair genes in cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine
por: Tong, Zhou, et al.
Publicado: (2020)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
por: Poon, Donald, et al.
Publicado: (2021)

TACC3 Is Essential for EGF-Mediated EMT in Cervical Cancer
por: Ha, Geun-Hyoung, et al.
Publicado: (2013)

Repurposing metformin for cancer treatment: current clinical studies
por: Chae, Young Kwang, et al.
Publicado: (2016)

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
por: Costa, Ricardo, et al.
Publicado: (2016)

Correction: TACC3 Is Essential for EGF-Mediated EMT in Cervical Cancer
por: Ha, Geun-Hyoung, et al.
Publicado: (2013)

TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis
por: Du, Yong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nvv3pgahf7gbicg0c72r77g8mo